Biomea Fusion (BMEA, Financial) received a consistent vote of confidence from D. Boral Capital analyst Jason Kolbert, who maintained a "Buy" rating on the stock. The price target also remains unchanged at $16.00.
According to the latest analyst update dated May 15, 2025, Biomea Fusion (BMEA, Financial) continues to be seen favorably by the analyst, with no adjustments made to either the rating or the price target from their previous assessment.
This reaffirmation suggests steady expectations for Biomea Fusion's (BMEA, Financial) market performance, as the price target and rating underscore the analyst’s ongoing positive outlook on the company's future prospects in the biotechnology sector.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 7 analysts, the average target price for Biomea Fusion Inc (BMEA, Financial) is $21.86 with a high estimate of $54.00 and a low estimate of $3.00. The average target implies an upside of 1,423.15% from the current price of $1.44. More detailed estimate data can be found on the Biomea Fusion Inc (BMEA) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Biomea Fusion Inc's (BMEA, Financial) average brokerage recommendation is currently 2.0, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
